Nature Communications (Mar 2024)

NFκB and NLRP3/NLRC4 inflammasomes regulate differentiation, activation and functional properties of monocytes in response to distinct SARS-CoV-2 proteins

  • Ilya Tsukalov,
  • Ildefonso Sánchez-Cerrillo,
  • Olga Rajas,
  • Elena Avalos,
  • Gorane Iturricastillo,
  • Laura Esparcia,
  • María José Buzón,
  • Meritxell Genescà,
  • Camila Scagnetti,
  • Olga Popova,
  • Noa Martin-Cófreces,
  • Marta Calvet-Mirabent,
  • Ana Marcos-Jimenez,
  • Pedro Martínez-Fleta,
  • Cristina Delgado-Arévalo,
  • Ignacio de los Santos,
  • Cecilia Muñoz-Calleja,
  • María José Calzada,
  • Isidoro González Álvaro,
  • José Palacios-Calvo,
  • Arantzazu Alfranca,
  • Julio Ancochea,
  • Francisco Sánchez-Madrid,
  • Enrique Martin-Gayo

DOI
https://doi.org/10.1038/s41467-024-46322-8
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 18

Abstract

Read online

Abstract Increased recruitment of transitional and non-classical monocytes in the lung during SARS-CoV-2 infection is associated with COVID-19 severity. However, whether specific innate sensors mediate the activation or differentiation of monocytes in response to different SARS-CoV-2 proteins remain poorly characterized. Here, we show that SARS-CoV-2 Spike 1 but not nucleoprotein induce differentiation of monocytes into transitional or non-classical subsets from both peripheral blood and COVID-19 bronchoalveolar lavage samples in a NFκB-dependent manner, but this process does not require inflammasome activation. However, NLRP3 and NLRC4 differentially regulated CD86 expression in monocytes in response to Spike 1 and Nucleoprotein, respectively. Moreover, monocytes exposed to Spike 1 induce significantly higher proportions of Th1 and Th17 CD4 + T cells. In contrast, monocytes exposed to Nucleoprotein reduce the degranulation of CD8 + T cells from severe COVID-19 patients. Our study provides insights in the differential impact of innate sensors in regulating monocytes in response to different SARS-CoV-2 proteins, which might be useful to better understand COVID-19 immunopathology and identify therapeutic targets.